Particularly in the regions of EMEA2 and the Americas, Sartorius Stedim Biotech benefited from additional demand in connection with the manufacture of coronavirus vaccines and Covid-19 therapeutics. Our strong business results once again underscore the strength and resilience of our strategy and business model. The Group companies are united under the roof of Sartorius AG, which is listed on the Frankfurt Stock Exchange and holds the majority stake in Sartorius Stedim Biotech S.A. for the last decade. SARTORIUS STEDIM BIO (A2AJKS | FR0013154002) mit aktuellem Aktienkurs, Charts, News und Analysen. In view of the strong results in 2020 and the forecasts regarding future organic growth potential, Sartorius Stedim Biotech has raised its mid-term targets. Sartorius has expanded its biopharmaceutical manufacturing facility Sartorius Stedim Campus, which is located in Yauco, Puerto Rico, US. The company said that a majority of the projected growth in business is due to the COVID-19 pandemic as many of its products are used in the manufacturing of vaccines. This page is also available in your prefered language. Sartorius Stedim … Sartorius Stedim Biotech, a leading international supplier for the biopharmaceutical industry, announced the launch of a full range of chemistry testing services. Sartorius Stedim Biotech recorded exceptionally dynamic growth in 2020 that was driven by strong organic development, several acquisitions and additional momentum from business related to the coronavirus pandemic. “The pandemic year of 2020 was exceptional and very challenging for Sartorius Stedim Biotech as well. Sartorius Stedim … Revenue in the Americas, which accounts for about 35 percent of total Group sales, rose sharply, also due to the acquisitions, by 34.0 percent to 670 million euros. ... GEN interviewed Reinhard Vogt, a member of the administrative board and executive vp of Sartorius Stedim Biotech. Für 360 Millionen Euro soll der slowenische Aufreinigungs­spezialist BIA Separations über­nommen und in die Tochter Sartorius Stedim Biotech ... Alle News zu COVID-19. Each and every day, we deliver essential products and technologies to manufacturers of coronavirus vaccine and medications for Covid-19 treatment all over the world – also beyond the current pandemic. The major part of the expected additional business is related to the coronavirus pandemic as many products of Sartorius Stedim Biotech are used for manufacturing vaccines. Completed in June 2019, construction of the expansion first began in 2016 with more than a $100m investment. Sartorius has presented its capacity to support the industry to develop and manufacture a COVID-19 vaccine in a series of webinars. In this joint effort, Sartorius Stedim Biotech is part of the solution. This page is also available in your prefered language. Il signe la deuxième meilleure performance du SBF 120, qui a abandonné 19% sur la période, juste derrière Biomérieux (+43%). Gerade wird die Pipeline der möglichen Covid-19-Impfstoffe weltweit beachtet. Sartorius Stedim Cellca is a subsidiary of Sartorius Stedim Biotech that has established innovative cell line development technology Cellca CHO Expression Platform. Particularly in the regions of EMEA 2 and the Americas, Sartorius Stedim Biotech benefited from additional demand in connection with the manufacture of coronavirus vaccines and Covid … Seite 1 der Diskussion 'Satorius Stedim Biotech, die attraktive Tochter von Sartorius' vom 25.06.2020 im w:o-Forum 'Biotech'. Universal Registration Document (complete), Consolidated Financial Statements and Notes (p. 125-191). We understand the urgency of the situation and we can help our customers manage various risks of vaccine discovery and production while maintaining quality and flexibility at this accelerated speed. Die Sartorius AG ist ein börsennotierter Pharma- und Laborzulieferer mit Sitz in Göttingen. Sartorius Stedim Biotech traverse la crise du Covid-19 avec une santé presque insolente. Sartorius Stedim Biotech continued its dynamic growth of the first half on into the third quarter. Switch to self version. Fachgebiet. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all … We bring our experience and solution portfolio to help our customers at all stages of vaccine development, from discovery and testing to large scale manufacturing against the novel SARS-CoV-2 outbreak. Particularly in the regions of EMEA 2 and the Americas, Sartorius Stedim Biotech benefited from additional demand in connection with the manufacture of coronavirus vaccines and Covid … The original French announcement is the legally binding version. Our data shows Sartorius Stedim Biotech has a return on equity of 20% for the last year. Furthermore, Sartorius Stedim Biotech reserves the right not to be responsible for the topicality, correctness, completeness or quality … We, at Sartorius, have been collaborators and suppliers to our biopharmaceutical customers in successfully developing and manufacturing vaccines for infectious disease outbreaks and pandemics like Ebola, Zika, H1N1 etc. Find out who we are, what we do and what drives us. ​​. Consolidated sales revenue is expected to rise to about 4 billion euros by 2025 (previous target: around 2.8 billion euros) and the underlying EBITDA margin to around 33% (former guidance: around 30%). Sartorius Stedim Biotech recorded exceptionally dynamic growth in 2020 that was driven by strong organic development, several acquisitions and additional momentum from business related to the coronavirus pandemic. With … Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. Sartorius Stedim Biotech continued its dynamic growth of the first half on into the third quarter. The company said that a majority of the projected growth in business is due to the COVID-19 pandemic as many of its products are used in the manufacturing of vaccines. Regarding profitability, the company forecasts that its underlying EBITDA margin will be about 32.0%, up from 31.7% a year earlier. Sartorius Stedim Biotech, a leading partner of the biopharma industry, closed the first nine months of 2020 with significant double-digit growth rates in sales revenue and earnings. It is important for society, especially amid the COVID-19 pandemic," said Mary Lavin. Depuis le 1 er janvier, le titre du fournisseur franco-allemand de l'industrie biopharmaceutique s'est envolé de 42% ! Euro. Impressively, Sartorius Stedim Biotech has grown EPS by 19% per year, compound, in the last three years. Sartorius Stedim Biotech, a leading partner of the biopharma industry, closed the first nine months of 2020 with significant double-digit growth rates in sales revenue and earnings. Sartorius Stedim Biotech is launching a new, scalable range of single-use bags. This page does not exist in your selected language. Sartorius Stedim Biotech: The rising star of European healthcare With the pandemic seeing sales of products facilitating vaccines and other Covid-related medicine soar, Sartorius’ turnover jumped 34.6% to €1.9 billion in 2020. The Group closed the year with significant double-digit growth rates in sales revenue, order intake and earnings, recording further gains across all geographies. Sartorius Stedim Biotech continued its dynamic growth of the first half on into the third quarter. Sorry, no results could be found for your search. Sartorius Stedim Cellca is developing the Cell Culture Technology Center (CCTC) in Science Park III in Germany, with an estimated investment of €30m ($35.2m). Sartorius Stedim will report its first quarter earnings on April 21. Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. sartorius stedim biotech fy underlying ebitda up at eur 604.7 million. Sartorius Stedim Biotech plans to grow profitably in 2021 as well. The content of our website is always available in English and partly in other languages. Your preference was saved and you will be notified once a page can be viewed in your language. Please select your country so we can show you products that are available for you. Sartorius Stedim Biotech recorded exceptionally dynamic growth in 2020 that was driven by strong organic development, several acquisitions and additional momentum from business related to the coronavirus pandemic. Particularly in the regions of EMEA 2 and the Americas, Sartorius Stedim Biotech benefited from additional demand in connection with the manufacture of coronavirus vaccines and Covid-19 therapeutics. The Group closed the year with significant double-digit growth rates in … The COVID 19 pandemic and the associated restrictions on life as we know it poses great challenges on every individual, both in our jobs and in our private lives. The company said that a majority of the projected growth in business is due to the COVID-19 pandemic as many of its products are used in the manufacturing of vaccines. From processes overviews to deep dives into specific technologies and Services, listen to our experts and feel free to contact us to engage in further discussions. Sartorius Stedim Biotech continued its dynamic growth of the first half on into the third quarter. ... Im Jahr 2007 fusionierte die Biotechnologiesparte von Sartorius mit den Franzosen zur Sartorius Stedim Biotech. So it's not surprising to see the company trades on a very high multiple of (past) earnings. Sartorius Stedim Biotech expects strong growth for 2021 and beyond. Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation. Sartorius Stedim will report its first quarter earnings on April 21. Biopharmaceutical Quality Control & Testing, Strong Acids, Bases, Alcohols & Detergents, Flexact® Modular | Single-use Automated Solutions, Hydrophobic Interaction Chromatography (HIC), Process Analytical Technology (PAT) & Data Analytics, Weighing Solutions (Special & Segment Solutions), MA Moisture Analyzers and Moisture Meters for Every Application, Laboratory- / Quality Management Trainings, Process Control Tools & Software Trainings. In this demanding environment, we were able to both achieve very substantial growth and close a few strategically very relevant acquisitions. SARS-CoV-2 (COVID-19) Vaccine research, testing, and production solutions, From Cell Line Development to Lot Release, Explore our portfolio that supports your drug development process, Field-Upgradeable, Label-Free Biomolecule Analysis Platform, Ensuring safe adoption of single-use systems in biopharmaceuticals. Consolidated sales revenue is thus projected to increase by about 20% to 26%. The need to accelerate time to market of novel therapeutic biologics has never been greater as the COVID-19 pandemic has scientists developing novel life-saving treatments at breakneck speed. Revenue in the Americas, which accounts for about 35 percent of total Group sales, rose sharply, also due to the acquisitions, by 34.0 percent to 670 million euros. Therefore, with the publication of the 2021 forecast, the company has also considerably raised its mid-term targets for 2025. Nine–month sales revenue increased by 29.2 percent (reported: 28.1 percent) to … SARS-CoV-2 (COVID-19) Vaccine Research, Testing, and Production Solutions, We, at Sartorius, have been collaborators and suppliers to our biopharmaceutical customers in successfully developing and manufacturing vaccines for infectious disease outbreaks and pandemics like Ebola, Zika, H1N1 etc. The company said that a majority of the projected growth in business is due to the COVID-19 pandemic as many of its products are used in the manufacturing of vaccines. And more than that: We are an essential contributor toward overcoming this pandemic; each and every day, we deliver essential products and technologies to vaccine manufacturers all over the world.”. This small nation has put Australia to shame in the global race to vaccinate populations against Covid. Particularly in the regions of EMEA 2 and the Americas, Sartorius Stedim Biotech benefited from additional demand in connection with the manufacture of coronavirus vaccines and Covid … In Paris, the company shares were trading at 365.60 euros, up 8 percent. Sartorius Stedim Biotech continued its dynamic growth of the first half on into the third quarter. (RTTNews) - French biopharmaceutical company Sartorius Stedim Biotech, affiliated to Germany's Sartorius AG (SDMHF.PK), announced Wednesday that it … Choose your preferred language and we will show you the content in that language, if available. for the last decade. The company said that a majority of the projected growth in business is due to the COVID-19 pandemic as many of its products are used in the manufacturing of vaccines. In Paris, the company shares were trading at 365.60 euros, up 8 percent. Based on very strong order intake during the first 10 weeks of 2021 and high demand expected to continue in the further course of the year, Sartorius Stedim Biotech has raised its growth forecast for fiscal 2021. Der Technologiekonzern erzielte im Jahr 2018 einen Umsatz von 1,566 Mrd. [3] Das 1870 gegründete Unternehmen beschäftigt über 8.000 Mitarbeiter. Particularly in the regions of EMEA2 and the Americas, Sartorius Stedim Biotech benefited from additional demand in connection with the manufacture of coronavirus vaccines and Covid-19 therapeutics. FDA Authorizes Lilly COVID-19 Antibody Combination for Emergency Use. Dear Valued Customers, Die Vorzugsaktien befinden sich zu rund 91 % im Streubesitz; rund 9 % werden vom Unternehmen selbst gehalten Nach einer erfolgreichen Kapitalerhöhung 1998 übernahm Sartorius ein Jahr später drei Unternehmen, unter anderem die Denver … /PRNewswire/ -- Sartorius Stedim Biotech, ... "This is an opportunity. Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. The company said that a majority of the projected growth in business is due to the COVID-19 pandemic as many of its products are used in the manufacturing of vaccines. Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently.